Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Infinity shares jumped 44% to $15.74 on the AbbVie deal announcement, reflecting market enthusiasm for the $275M upfront and 23.5-30.5% ex-US tiered royalties…
AbbVie CSO Michael Severino called duvelisib 'a very promising investigational treatment based on clinical data showing activity in a broad range of blood…
Retrospective coverage describes duvelisib as the 'AbbVie-abandoned lymphoma drug' that AbbVie walked away from in 2016 after weak Phase 2 iNHL data, before…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie paid Infinity $275M upfront plus up to $530M in development and regulatory milestones plus tiered royalties for global rights to duvelisib, a dual PI3K-delta/gamma inhibitor in late-stage development for hematologic cancers. AbbVie returned rights in 2016; duvelisib (Copiktra) eventually commercialized by Verastem.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Infinity Pharmaceuticals, Inc. (this deal) | 2014 | $805M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2014 deals · AbbVie Inc. deals · Hematology deals